Subscribe to our newsletter.
5FU DPYD is an individual’s ability to metabolize the chemotherapy drug 5-Fluorouracil (5FU), which is commonly used to treat various types of cancer. The metabolism of 5FU is primarily regulated by the enzyme dihydropyrimidine dehydrogenase (DPYD). Genetic mutations in the DPYD gene can result in reduced or absent enzyme activity, leading to severe toxicity when standard doses of 5FU are administered. Patients with compromised DPYD function may experience extreme side effects, including life-threatening conditions like neutropenia or neurotoxicity. Genetic testing for DPYD variants is increasingly recognized as an important step in personalized cancer treatment, allowing clinicians to tailor 5FU dosage to individual metabolic capacity.